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Abstract
Background: In muscle cytochrome oxidase (COX) negative fibers (mitochondrial mosaics) have
often been visualized.
Methods: COX activity staining of liver for light and electron microscopy, muscle stains, blue
native gel electrophoresis and activity assays of respiratory chain proteins, their
immunolocalisation, mitochondrial and nuclear DNA analysis.
Results: Three unrelated infants showed a mitochondrial mosaic in the liver after staining for COX
activity, i.e. hepatocytes with strongly reactive mitochondria were found adjacent to cells with
many negative, or barely reactive, mitochondria. Deficiency was most severe in the patient
diagnosed with Pearson syndrome. Ragged-red fibers were absent in muscle biopsies of all patients.
Enzyme biochemistry was not diagnostic in muscle, fibroblasts and lymphocytes. Blue native gel
electrophoresis of liver tissue, but not of muscle, demonstrated a decreased activity of complex IV;
in both muscle and liver subcomplexes of complex V were seen. Immunocytochemistry of complex
IV confirmed the mosaic pattern in two livers, but not in fibroblasts. MRI of the brain revealed
severe white matter cavitation in the Pearson case, but only slight cortical atrophy in the Alpers-
Huttenlocher patient, and a normal image in the 3rd. MtDNA in leucocytes showed a common
deletion in 50% of the mtDNA molecules of the Pearson patient. In the patient diagnosed with
Alpers-Huttenlocher syndrome, mtDNA was depleted for 60% in muscle. In the 3rd patient
muscular and hepatic mtDNA was depleted for more than 70%. Mutations in the nuclear encoded
gene of POLG were subsequently found in both the 2nd and 3rd patients.
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Conclusion: Histoenzymatic COX staining of a liver biopsy is fast and yields crucial data about the
pathogenesis; it indicates whether mtDNA should be assayed. Each time a mitochondrial disorder
is suspected and muscle data are non-diagnostic, a liver biopsy should be recommended. Mosaics
are probably more frequent than observed until now. A novel pathogenic mutation in POLG is
reported.
Tentative explanations for the mitochondrial mosaics are, in one patient, unequal partition of 
mutated mitochondria during mitoses, and in two others, an interaction between products of 
several genes required for mtDNA maintenance.
Background
Mitochondrial heterogeneity after cytochrome oxidase
staining has often been visualized in muscle [1-15].
Whether this is caused by varying proportions of mutant
and/or depleted versus wildtype mtDNA, has not (com-
pletely) been elucidated. Müller-Höcker [16] using COX
histochemistry demonstrated a mosaic in the liver of an
infant with encephalopathy, cholestatic giant cell hepati-
tis and mtDNA depletion of unknown origin.
Pearson syndrome (PS) (moderate psychomotor retarda-
tion, pancytopenia and pancreatic insufficiency; MIM
557000) and Alpers-Huttenlocher syndrome (AHS)
(myoclonal epilepsy, liver and brain disease; MIM
203700) are known to harbour defects of mitochondrial
function [17-19], but mitochondrial mosaics in the liver
have not been described.
We report on a 2.5 year old girl with PS, a 1-year old boy
with AHS, and a 3-year old girl with mtDNA depletion; all
show mosaics in their liver parenchyma. In contrast non-
parenchymal cells appear microscopically normal.
Partial results were published in abstract form [20].
Methods
Muscle stains included Gomori-trichrome, fiber typing by
ATP-ase after preincubation at pH 4.6, and localisation of
COX-and NADH-TR activities according to standard reci-
pes [21]. In the liver cytochrome oxidase activity was vis-
ualized with diaminobenzidine according to Seligman et
al [22], as modified by Novikoff & Goldfischer [23].
Briefly, liver samples were prefixed in 1% cold buffered
glutaraldehyde for 2 hrs in order to preserve ultrastruc-
ture. After rinsing, cryostat sections were incubated in
open vials at 37° in a DAB medium at pH 6 in acetate
buffer containing 0.005 M MnCl2, with and without
added cytochrome c (1 mg/10 ml) for 2 and 4 hrs. DAB
staining of mitochondria was shown to be both O2 and
cytochrome c dependent [24,25]. For light microscopy
(LM) 7 μm sections were mounted in aquamount; for
electron microscopy 60 μm sections were postfixed in 1%
OsO4. Semithin sections were also examined by LM.
Enzymes and metabolites of oxidative phosphorylation
were measured in liver, cultured fibroblasts, lymphocytes
or muscle.
Blue native PAGE was performed on liver or muscle
homogenate as described [26]. MtDNA was analysed by
RT-PCR in muscle or leucocytes or liver according to
[27]The nuclear gene POLG encoding polymerase gamma
was sequenced as described [28].
For immunocytochemistry cytospins of cultured fibrob-
lasts were prepared and stained as described [29]. Of liver
tissue 8 μm paraffin sections were deparaffinized in
xylene and rehydrated in ethanol solutions. After blocking
with 2.5% BSA in PBS for 30 min, sections were incubated
with primary antibodies in the same solution during 2
hours at room temperature. For the detection of each of
the five complexes of the oxidative phosphorylation,
monoclonal antibodies were selected that were directed
against the gene products of NDUFS7, SDHB, UQCRC2,
MTCO1 and ATP5A1 (Invitrogen). Immunodetection was
accomplished with the alkaline phosphatase labelled
EnVision polymer (Dako) and fast red chromogen. Nuclei
were counterstained with hematoxylin and slides were
mounted with aquatex.
Ethical issues: all tests and investigations reported in this
paper were carried out for diagnostic purposes in the
interest of the patients, and under the authority of the uni-
versity hospitals involved. In particular the parents gave
approval for the muscle and liver biopsies, as well as for
publication.
Results
Patients
Patient 1, the daughter of non-consanguineous parents,
presents with slight pancytopenia (hemoglobin 9 g/dL,
leucocytes 3–5000/ml) and exocrine pancreatic dysfunc-
tion (lipase up to 700 U/L but amylase normal). In addi-
tion there is moderate psychomotor retardation; at 3 y she
is not walking, and talks little. A diagnosis of Pearson syn-
drome is proposed. MRI shows bilateral cavities in the
frontal white matter and right occipital lobe (figures 1a, b,BMC Clinical Pathology 2009, 9:4 http://www.biomedcentral.com/1472-6890/9/4
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c, d) and absence of the lactate spectrum. Muscle and liver
biopsies are performed at 2.5 y. She dies when 3 y 3 m old.
Patient 2 is the son of unrelated parents. His uncle suf-
fered from temporal epilepsy. He presents with focal myo-
clonal epilepsy, axial hypotonia and moderately elevated
liver enzymes in the serum (AST 150, 172, 601 U/L; ALT
102, 88, 299 U/L; gGT 83, 93 IU/L). Blood lactate is high.
A first MRI at the age of 11 m is normal; but when
repeated 4 weeks later it shows slight diffuse cortical atro-
phy (figures 2a, b, c, d). This leads to the tentative diagno-
sis of Alpers-Huttenlocher. A muscle biopsy and, at 13 m,
a liver biopsy are performed. He dies at 3 y 1 m of age.
Patient 3. Is the daughter of non-consanguineous parents
and has normal birthweight. At 3.5 months severe
hypoglycemia without ketosis is detected. Hypoglycemia
and high blood lactate persist during a fast longer than 5
hrs; it is irresponsive to glucagon. The patient has no car-
diomyopathy. Acylcarnitine, sialotransferrine, tyrosine-
mia, galactosemia and urine organic acids are within
normal range. Palmitate and oxanoate oxidation in cul-
tured fibroblasts is normal. Transaminases are increased,
and a liver biopsy shows micronodular cirrhosis; glucose-
6-phospatase activity is normal. A muscle biopsy and a
second liver biopsy are taken at 18 m. MRI is normal at the
age of 2 years. At 3 y 9 m, status epilepticus develops
which occurs again at 4 y and is difficult to control; and
again at 4 y 10 m. At 4 y 11 m there is status epilepticus
with myoclonia despite general anaesthesia. She dies from
bronchopulmonary infection when 5 y old. The parents
agree to an autopsy. This patient is studied in more detail
in (Emmanuel Scalais and Baudouin François, in prepara-
tion)
Pathology, biochemistry and molecular biology
Mitochondrial metabolites and respiratory chain activities
in muscle or fibroblasts were unremarkable in all three
patients. In the liver of patients 1 and 3 complex IV activ-
ity was decreased (Additional file 1).
Muscles did not show ragged-red fibers; fiber types were
normally distributed at random and of comparable sizes
(figures 3a, b). COX activity showed normal chess-board
distribution of dark type 1 fibers (figure 3c). In patient 2
COX activity seemed diminished, but this can be due to
the delay between sampling and staining. Mitochondrial
distribution visualized by NADH-TR was always normal
(figure 3d).
Blue native PAGE of liver of patient 1 demonstrated very
low complex IV (cytochrome oxidase) activity, and a
slightly decreased activity in the liver of patient 3, but it
was normal in muscle of patients 2 and 3. Complex V
(mitochondrial ATP-ase) revealed subcomplexes in
patient 1, and in both tissues of patient 3 (figure 4).
Liver histology
micro- and macrovesicular steatosis is seen in patients 2
and 3. In patient 2 reticulin lining of hepatocytes was
Patient 1, brain MRI Figure 1
Patient 1, brain MRI. 1a: TRACE sequence shows cyto-
toxic oedema in frontoparietal white matter bilaterally, and 
in right occipital. 1b: FLAIR sequence, right occipital and 
bilateral frontoparietal lesions; compare to fig 1a. 1c: 5 
months later. T1 weighted without iv contrast. Bifrontal 
white matter loss with lacunae, small lacuna in right occipital. 
1d: Coronal section; bilateral loss of white matter; lacunae 
lined by high signal interpreted as gliosis.
Patient 2, brain MRI Figure 2
Patient 2, brain MRI. 2a: T2 weighted; mild tot moderate 
dilatation of ventricles and peripheral liquor spaces suggest-
ing cerebral atrophy. 2b: TRACE sequence shows cytotoxic 
oedema in cortex of right central gyrus. 2c: 3 months later. 
Focal cortical atrophy of central gyrus bilaterally. 2d: 2 years 
later. Focal cortical atrophy of central gyrus bilaterally.
a a a a b b b b
c c c c d d d dBMC Clinical Pathology 2009, 9:4 http://www.biomedcentral.com/1472-6890/9/4
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thicker or double, and after CK7 immunoreaction, meta-
plasia of the parenchyma was detected. Both features sug-
gest a reaction to earlier cell death. However no signs of
ongoing necrosis were seen.
In the liver of patient 3 micronodular cirrhosis was obvi-
ous, and was even more severe at autopsy (figure 5a).
Kupffer cells contained many PAS-positive granules that
often were large; they stained positive for acid phos-
phatase. By electron microscopy as well these lysosomes
were conspicuous, but their contents were not suggestive
of a specific storage disorder.
Cytochrome oxidase localisation in liver
by LM the DAB staining reaction appeared negative in sev-
eral liver sections of patients 1 and 3, however in other
areas of the biopsy fragments, islets of hepatocytes were
found that reacted for COX activity (figures 5b, 6a, b). In
patient 2 COX stained regions alternated with weakly
staining and unstained ones (figures 7a, b). Sometimes
single hepatocytes with stained mitochondria were sur-
rounded by unstained cells. Total area with active COX
was estimated to be larger than the unstained areas in pt
2; in contrast COX positive cells were a minority in
patients 1 and 3, approximately 10% in patient 3. In
patients 2 and 3 bile duct epithelium and arterial smooth
muscle cells revealed granular, i.e. mitochondrial stain-
ing.
Addition of cytochrome c to the reaction medium did not
result in a convincing increase of staining in either patient,
indicating that endogenous cytochrome c was not rate-
limiting.
By electron microscopy parenchymal cells with a strong
reaction in inner mitochondrial membrane and cristae
were found adjacent to cells with mitochondria without
visible contrast and mitochondria with one or two cristae
that reacted (figures 8, 9, 10, 11, 12, 13). The latter
organelles are expected to be invisible by LM. In some of
these organelles cristae appeared scarce and/or misshapen
(figures 12, 13). In all 3 patients most mitochondria had
too few or no cristae by ultrastructural morphology; mito-
chondrial number seemed to be increased (figures 8, 10)
but this was not evident in all hepatocytes. In patient 3 sev-
eral mitochondria showed invaginations of their envelope
containing cytoplasm and glycogen rosettes (figure 13).
In patients 1 and 2 the small mitochondria of bile duct
epithelial cells, vascular smooth muscle, endothelial cells,
Muscle pathology Figure 3
Muscle pathology. 3a: ATP-ase reaction at pH 4.6 shows 
regular sizes and normal chessboard distribution of 3 fiber 
types. Patient 2. 3b: Gomori trichrome shows normal image; 
absence of ragged-red fibers. Patient 1. 3c: Cytochrome oxi-
dase activity shows normal distribution of mitochondria in 
distinct fiber types; compare to 3d. Patient 3. 3d: NADH-
tetrazolium reductase shows normal distribution of mito-
chondria; compare to COX stain in 3c. Patient 1.
a b
c d
Blue native PAGE of the OXPHOS complexes Figure 4
Blue native PAGE of the OXPHOS complexes. In-gel 
activity staining. In patient 1 (Pearson syndrome), the activity 
of complex IV is severely decreased in liver. In patient 2 
(POLG mutation), complex I and complex II are slightly 
decreased in skeletal muscle (a limited amount of muscle 
from the patient was available for testing and the complex II 
band was weak in the control as well). Normal activities are 
detected in mitochondria from skeletal muscle of patient 3 
(POLG mutation). In liver mitochondria of this patient the 
activities of complex I, III and IV are slightly decreased. In 
mitochondria from all patients subcomplexes of complex V 
are seen (only weakly in patient 2), which is considered as a 
marker of disturbed intramitochondrial protein synthesis.BMC Clinical Pathology 2009, 9:4 http://www.biomedcentral.com/1472-6890/9/4
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Kupffer cells and neutrophils reacted strongly, adjacent to
parenchyma with poorly reactive mitochondria (figures
14, 15). Also in patient 3 positive mitochondria were seen
in a non-parenchymal cell.
Glycogen rosettes were abundant in the parenchymal
cytosol in the three livers, as is usual in well-fed infants.
Steatosis in the liver of patient 2 was considerable in both
hepatocytes with well stained or unstained mitochondria.
Since cells with minimal COX reaction showed no
ultrastructural signs of anoxia or cell damage, such as
dilated ER or swollen mitochondria, a primary mitochon-
drial enzyme defect is most likely.
Liver, patient 3 Figure 5
Liver, patient 3. 5a: micronodular cirrhosis at 18 months; 
trichrome stain. 5b: small group of COX reactive parenchy-
mal cells adjacent to an unstained region. Cryostat section, 
cytochrome oxidase reaction, nuclei slightly counterstained 
with methylgreen.
b
Liver, patient 1, cytochrome oxidase stain Figure 6
Liver, patient 1, cytochrome oxidase stain. 6a: low 
power view of cryostat section; islet of stained cells sur-
rounded by unstained parenchyma. Large dark granules are 
erythrocytes in sinusoids and Kupffer cells that stain for per-
oxidase (arrow). Patient 1. 6b: high power of sharp border 
between COX stained and unstained parenchymal cells. 
Numerous tightly packed granules are mitochondria. In the 
unstained cells, the fewer small round granules are peroxi-
somes reacting by their catalase. Postosmicated, semithin 
plastic section.
a b
Liver, patient 2, cytochrome oxidase stain Figure 7
Liver, patient 2, cytochrome oxidase stain. 7a: Differ-
ent levels of mitochondrial staining in adjacent hepatocytes, 
cryostat section. Nuclei slightly counterstained with methyl-
green reveal cells without staining (arrow). 7b: Higher magni-
fication: COX-positive parenchymal cells alternate with 
unstained ones. Large dark structures are erythrocytes 
(arrow). Nuclei slightly counterstained with methylgreen, 
cryostat section.
ab
Liver: ultrastructure and reaction for cytochrome oxidase Figure 8
Liver: ultrastructure and reaction for cytochrome 
oxidase. Fig 8: COX reaction product stains mitochondrial 
envelope and cristae. 4 parenchymal cells have different lev-
els of mitochondrial reaction. Peroxisomes are dark round 
bodies (arrows), they stand out in the hepatocyte without 
COX reaction; here mitochondrial numbers appear 
increased. Patient 1.BMC Clinical Pathology 2009, 9:4 http://www.biomedcentral.com/1472-6890/9/4
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COX reaction: parenchymal cell in the center shows mito- chondria devoid of reaction product Figure 9
COX reaction: parenchymal cell in the center shows 
mitochondria devoid of reaction product. It is sur-
rounded by cells with well-stained mitochondria. Tiny gran-
ules are glycogen. Patient 2.
COX reaction: 2 hepatocytes with well-contrasted mito- chondrial envelopes and cristae Figure 10
COX reaction: 2 hepatocytes with well-contrasted 
mitochondrial envelopes and cristae. In the third cell 
that contains many lipid globules, only some mitochondria 
have a few stained cristae (arrow); mitochondrial numbers 
appear increased. Patient 2.
COX reaction: only single or few cristae show COX reac- tion product Figure 11
COX reaction: only single or few cristae show COX 
reaction product. Large lipid globules are either dark, grey 
or largely dissolved. Tiny dark granules are glycogen. Patient 
3.
COX reaction: mitochondrion (asterisk) with only two circu- lar cristae reacting; other mitochondria in this hepatocyte  are unstained Figure 12
COX reaction: mitochondrion (asterisk) with only 
two circular cristae reacting; other mitochondria in 
this hepatocyte are unstained. Adjacent cell shows 
strongly reacting mitochondrial envelopes and cristae; also 
lipid. Dark bodies are peroxisomes (arrows). Patient 1.
*BMC Clinical Pathology 2009, 9:4 http://www.biomedcentral.com/1472-6890/9/4
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Immunocytochemistry of OXPHOS proteins
the livers of patients 2 and 3 displayed a mosaic staining
pattern for both complexes I and IV (figure 16a). Immu-
noreactivity for complexes II, III and V was preserved in all
liver cells (figure 16b).
In cultured fibroblasts from patient 2, a mosaic of positive
and negative cells was observed for complex I; in contrast
complexes II, III, IV and V were revealed in all cells.
Fibroblasts from patient 3 displayed immunostaining in
all cells.
DNA analysis
in patient 1 (leukocytes) a "common" deletion of 4977 bp
in 50% of the mtDNA molecules was found, in agreement
with earlier cases of Pearson syndrome.Patient 2: muscle
COX reaction: Single reacting semicircular crista Figure 13
COX reaction: Single reacting semicircular crista. 
Other mitochondria are (nearly) unreactive; two show 
invaginations (arrow) containing glycogenrosettes and 
cytosol. Patient 3.
COX reaction in non-parenchymal cells Figure 14
COX reaction in non-parenchymal cells. COX reac-
tion: numerous well stained mitochondria in lining cells of a 
bile duct (or capillary); a basal lamina is present. Adjacent 
hepatic parenchyma shows dark peroxisomes while mito-
chondria have only a few reactive cristae. Patient 1.
COX reaction: strongly reactive mitochondria in a cell iden- tified by its microfilaments as vascular smooth muscle Figure 15
COX reaction: strongly reactive mitochondria in a 
cell identified by its microfilaments as vascular 
smooth muscle. Patient 1.
Immunocytochemistry of OXPHOS proteins in liver of  patient 3 Figure 16
Immunocytochemistry of OXPHOS proteins in liver 
of patient 3. 16a: complex IV (coloured red) is present only 
in islets of cells amid unstained parenchyma. 16b: complex II 
is present in red granules, i.e. in mitochondria in all parenchy-
mal cells.
a bBMC Clinical Pathology 2009, 9:4 http://www.biomedcentral.com/1472-6890/9/4
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showed 60% depletion of the mtDNA content by real
time quantitative PCR analysis, and no mutation of
mtDNA, in agreement with the clinical diagnosis of Alp-
ers-Huttenlocher syndrome. Subsequent analysis of the
nuclear DNA showed a heterozygous recessive mutation
in the POLG gene, predicting an A467T amino acid substi-
tution [28] in combination with a previously unreported
heterozygous recessive splice site mutation c.3643+2t>c.
We also sequenced DNA of both parents, and the father
carried the A467T mutation only, whereas the splice site
mutation was present in the mother. This finding con-
firms that both mutations are located on different alleles
and suggests that the combination of these mutations is
very likely to cause the patients phenotype. Furthermore,
the novel mutation alters an evolutionary conserved
splice site and is located in the splice donor GT sequence,
which is functionally important in the splicing process.
Online tools predict that the donor site cannot be recog-
nized as such because of this sequence alteration (e.g.
http://bioinfo.itb.cnr.it/oriel/splice-view.html). We con-
clude that the c.3643+2T>C mutation is a genuine novel
pathogenic mutation in POLG.
Patient 3: real time PCR quantification of mtDNA showed
a depletion of 74% and 74% of mtDNA contents in mus-
cle and liver, respectively. POLG  sequencing showed 2
heterozygous recessive mutations, predicting A467T and
G848S aminoacid substitutions [28,30].
Discussion
Although mitochondrial mosaics after COX staining have
been known in skeletal muscle and myocardium since
1983, only a single case has been reported in liver [16].
COX histochemistry can be carried out within 24 hrs and
is easy to perform. In our patients it yielded evidence,
already by light microscopy, of the underlying pathologi-
cal mechanism, i.e. partial defects in COX activity,
whereas tests in blood and muscle were normal or not
helpful. The COX deficiency directed subsequent analysis
towards blue native electrophoresis of the OXPHOS pro-
teins and to mtDNA.
It is striking that COX activity in skeletal muscle cells, vis-
ualized also with DAB, had a normal pattern. Non-paren-
chymal cells in the liver appeared not to participate in the
mosaics, which were limited to the hepatic parenchyma,
an observation also made by Müller-Höcker et al [16]. But
considering the clinical symptoms it is likely that brain
cells, exocrine pancreas and bone marrow had COX defi-
ciency as well. Mild brain atrophy on MRI and psychomo-
tor retardation were also present in the patient of Müller-
Höcker et al.
When interpreting the absence of, or very weak stain in
single mitochondria at ultrastructure, it should be recalled
that the tissue was prefixed in aldehyde which inhibits
part of COX activity. One can speculate therefore that liver
cells devoid of DAB stain, were actually not entirely with-
out COX activity. Indeed it would be difficult for a cell
without any COX to survive for long.
How can the cell- and tissue heterogeneity of the COX
activity be explained?
Many disorders have been linked to heteroplasmic altera-
tions in mtDNA: in muscle [6], liver [31], cardiomyocytes
and other tissues. Clinical syndromes associated with het-
eroplasmy are several types of myopathy [5,6]; myoclonus
epilepsy and ragged red fibers (MERRF) [4]; progressive
external ophtalmoplegia, childhood optic atrophy, fol-
lowed by deafness and ataxia later [8]; dilated cardiomy-
opathy [32]; multiple lipomas [33]; Kearns-Sayre
syndrome (MIM 530000)[34,35]; focal segmental
glomerulosclerosis [36]; early onset diabetes mellitus,
optic atrophy and deafness (Wolfram syndrome)[37];
Alpers-Huttenlocher-like disease [31]; and Pearson syn-
drome with Kearns-Sayre encephalomyopathy [9].
The histochemical COX staining in individual muscle fib-
ers appears to be linked to the expression of a mutation in
mtDNA [4] and heterogeneous defects in COX activity
may be due to differing populations of wildtype and
mutant mtDNA ([10]. Hudson et al [8] showed that COX-
positive vs. negative fibers in muscle are correlated to their
level of mtDNA deletion.
In patient 1, the observed deletion in the mtDNA that
encodes for the complex IV protein, might be limited to
part of the liver parenchyma if this mutation was gener-
ated early during liver histogenesis in a single cell hitting
only its descendants. But also blood cells bear the muta-
tion (it was found there). There is no simple model for a
common origin of both celltypes, blood cells and (part) of
the hepatocytes; less so for the neurons and most glia in
the brain some of which must have low COX activity.
A different mechanism proposes that the mutation inter-
vened early in development, possibly even in the oocyte,
that both mutated as well as wild-type mitochondria pro-
liferated but were distributed at random in the daughter
cells, and thus not equally in every cell. This results in var-
ying proportions of normal and defective mitochondria
per cell, so-called "shift", or "drift" of the genotype [38].
Larsson et al [35] concluded that "the phenotype can
change with time and is governed by fractional concentra-
tion in different tissues of the mtDNA with the deletion".
Chinnery et al [5] think it is likely that the progression inBMC Clinical Pathology 2009, 9:4 http://www.biomedcentral.com/1472-6890/9/4
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time of the COX defect in muscle "is due to clonal expan-
sion of mutant mtDNA". The frequently observed
sequence in Pearson syndrome of early hematopoietic
dysfunction followed later by lactic acidosis, pancreas dys-
function and symptoms of Kearns-Sayre syndrome, has
been tentatively explained by "chance distribution of the
deleted molecules among the tissues through redistribu-
tion" [39]. COX-negative, but also ragged-red muscle fib-
ers (absent in our case) were found in a 8-year old boy
who combined the symptoms of Pearson and Kearns-
Sayre syndromes [9]. Moreover, we speculate that cell
death, ensuing each time COX activity falls below the sur-
vival threshold, will trigger compensatory hyperplasia in
those tissues that are capable of regeneration, and enable
an enrichment with COX-positive cells, i.e. among liver
cells of all types, lymphocytes and bone marrow cells,
and, in young individuals, even brain cells: glia no doubt,
and perhaps even neurons. In neurons proliferative capac-
ity quickly regresses with age; this might explain why the
neonate was symptom-free but subsequently developed
progressive lesions leading to death.
That cultured fibroblasts of our patients gave normal tests
is not unexpected: the phenotypic expression of respira-
tory chain disorders is unstable in cultured cells and tends
to return to normal values [38,40]. In their recent review
on disorders of mtDNA synthesis, Freisinger et al. state
that fibroblasts are not suitable for assays of depletion
[41]. A possible explanation is that cultured cells originate
from mothercells that have wild-type mtDNA while the
mutated cells die or do not proliferate.
A mosaic of COX activity in muscle has also been
observed in a case of a homoplasmic mutation of mtDNA
[14]; this is more difficult to explain.
On the other hand patients 2 and 3 had a large depletion
of the amount of mtDNA.
Depletion syndromes are associated with nuclear muta-
tions of DGUOK [42], SUCLA2, SUCLG1, TK2, MPV17
[43], PEO1 [44], RRM2B, and POLG; the last is the case in
two of our patients. Mutations in the POLG gene were pre-
viously reported in AHS by three groups [17-19,45-47]
and most recently by Stewart et al. [15] who describe 9
patients with a COX mosaic in muscle, but none in liver.
How can one explain a mitochondrial mosaic linked to a
nuclear mutation?
Comparing muscle of two patients Moraes et al [48]
found a correlation between the degree of mtDNA deple-
tion and COX activity. Since the reduction of mtDNA in
cell cultures results in gradual loss of respiratory rate and
COX activity [49], the question can be rephrased as fol-
lows: why is the level of depletion varying between indi-
vidual mitochondria, individual cells, and tissues?
Models for tissue specificity of the expression of nuclear
mutations impairing the enzymes required for mtDNA
synthesis are proposed by several groups; they are based
on interactions of distinct gene products required for this
synthesis, enzymes as well as metabolites.
In muscle the dNTP transporter securing import of
cytosolic deoxyribonucleotides for mtDNA synthesis, is
normally low. Partial loss by a mutation of the mitochon-
drial enzyme thymidine kinase-2 will result in critically
low levels of DNA. In contrast other celltypes where more
dNTP transporter is available will be spared although the
mutation is present [50-53].
In brain a mutation of succinyl-CoA synthetase-A
(required for ADP synthesis) combined to a normally very
low mitochondrial NDPKinase (that phosphorylates
ADP) will again result in shortage of precursors and thus
depletion of DNA [51]. Other tissues have more dNDPK.
The cytosolic deoxycytosinekinase has an overlapping
substrate specificity with deoxyguanosinekinase. But in
liver and brain it is normally very low; a mutation of deox-
yguanosinekinase cannot be compensated and will result
in DNA depletion limited to those tissues [52] or more
severe than in muscle [53]. Vice versa, Taanman et al. have
shown that supplementation of dGMP and dAMP to
fibroblasts can prevent mtDNA depletion [54]. Hepatic
and brain-specific phenotypes are known in mutations of
deoxyguanosine kinase [55], and reversal of the pheno-
type was also described [56].
Sarzi et al. discussing two sibs with a hepatocerebral syn-
drome and a TWINKLE mutation, suggest that tissue spe-
cific differences of nucleotides as well as the normally
higher activity of helicase in muscle compared to liver
explain the organ specificity of the disease [57].
Galassi et al., discussing a patient with one mutation in
POLG-A and a second in ANT1, mention the possibility
that the complex clinical features "may be due to cooper-
ative effects consequent to the interrelation of two mito-
chondrial functions both converging on the homeostatic
control of mtDNA maintenance and stability" [58].
Another mechanism for variability in phenotypic expres-
sion and possibly for tissue- and cell-specific deficiency is
reversal of the mutation in the TK2  gene that caused
mtDNA depletion [59].
When liver is compared to muscle, in 4 unrelated children
with AHS, there was respiratory chain enzyme deficiencyBMC Clinical Pathology 2009, 9:4 http://www.biomedcentral.com/1472-6890/9/4
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in liver, but not in muscle [60]. In a recent series of 10
children with mutations in POLG1, 5 had normal
enzymes in muscle [61]. The authors conclude that the
assay of mitochondrial enzymes in muscle alone is not
effective. Mutations in DGUOK causing mtDNA depletion
nearly always result in normal muscle enzymes, and the
study of liver is recommended [41]. The patients with the
mutation in PEO1 had a severe reduction of OXPHOS
complexes in the liver and not in muscle [57]. In a large
series of patients with mtDNA depletion and mutations in
DGUOK, POLG, MPV17 or TK2, 17 cases had lowered res-
piratory enzymes in liver but normal activities in muscle
[62].
Given the frequency of tissue heterogeneity, mitochon-
drial mosaics in liver may be more frequent than reported
until now.
Whether mosaics after COX staining of the liver were
present in these cases from the literature has not been
studied.
Finally it is tempting to speculate on the relationship
between clinical severity and proportions of COX defi-
cient mitochondria in the mosaics. In patient 1 by far the
smallest ratio of stained/unstained mitochondria in the
liver coexisted with the severest brain lesions on MRI; on
the other hand liver transaminases were unremarkable.
Hepatic disease was more pronounced in the AH patient,
as estimated by the liver enzymes AST, ALT and gGT. The
3rd patient's liver, with 10% of the hepatocytes with react-
ing mitochondria, had already developed cirrhosis at 3
months of age, but cerebral symptoms appeared only 3
years later. When taking into account the extraordinary
regenerative capacity of liver parenchyma, and the near
absence of such capacity in the brain, we see as yet no sim-
ple correlation between disease severity and the observed
distribution of COX deficiency in the liver.
Conclusion
A tentative explanation for the mitochondrial mosaics is,
in patient 1, unequal partition of mutated mitochondria
during mitoses, and in patients 2 and 3, an interaction
between products of several genes required for mtDNA
maintenance.
Histoenzymatic COX staining of a liver biopsy is fast and
yields crucial data about the pathogenesis; it indicates
whether mtDNA should be assayed. Each time muscle
data are non-diagnostic, a liver biopsy should be recom-
mended. Mosaics are probably more frequent than
observed until now.
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